26 related articles for article (PubMed ID: 16488611)
1. Metabolism and hydrophilicity of the polarised 'Janus face' all-
Rodil A; Bosisio S; Ayoup MS; Quinn L; Cordes DB; Slawin AMZ; Murphy CD; Michel J; O'Hagan D
Chem Sci; 2018 Mar; 9(11):3023-3028. PubMed ID: 29732086
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and supramolecular properties of all-
Haridas SV; von Delius M
Chem Commun (Camb); 2024 Jan; 60(5):606-609. PubMed ID: 38099916
[TBL] [Abstract][Full Text] [Related]
3. Comparative assessment of (18) F-Mefway as a serotonin 5-HT1A receptor PET imaging agent across species: Rodents, nonhuman primates, and humans.
Mukherjee J; Bajwa AK; Wooten DW; Hillmer AT; Pan ML; Pandey SK; Saigal N; Christian BT
J Comp Neurol; 2016 May; 524(7):1457-71. PubMed ID: 26509362
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and Evaluation of Mefway Analogs as Ligands for Serotonin 5HT
Thio JP; Liang C; Bajwa AK; Wooten DW; Christian BT; Mukherjee J
Med Chem Res; 2015 Apr; 24(4):1480-1486. PubMed ID: 25750500
[No Abstract] [Full Text] [Related]
5. Initial in vivo PET imaging of 5-HT1A receptors with 3-[(18)F]mefway.
Wooten DW; Hillmer AT; Murali D; Barnhart TE; Thio JP; Bajwa AK; Bonab AA; Normandin MD; Schneider ML; Mukherjee J; Christian BT
Am J Nucl Med Mol Imaging; 2014; 4(5):483-9. PubMed ID: 25143866
[TBL] [Abstract][Full Text] [Related]
6. An in vivo comparison of cis- and trans-[18F]mefway in the nonhuman primate.
Wooten D; Hillmer A; Murali D; Barnhart T; Schneider ML; Mukherjee J; Christian BT
Nucl Med Biol; 2011 Oct; 38(7):925-32. PubMed ID: 21741252
[TBL] [Abstract][Full Text] [Related]
7. 5-HT radioligands for human brain imaging with PET and SPECT.
Paterson LM; Kornum BR; Nutt DJ; Pike VW; Knudsen GM
Med Res Rev; 2013 Jan; 33(1):54-111. PubMed ID: 21674551
[TBL] [Abstract][Full Text] [Related]
8. Applications of LC-MS in PET radioligand development and metabolic elucidation.
Ma Y; Kiesewetter DO; Lang L; Gu D; Chen X
Curr Drug Metab; 2010 Jul; 11(6):483-93. PubMed ID: 20540692
[TBL] [Abstract][Full Text] [Related]
9. Application of highly sensitive UPLC-MS to determine biodistribution at tracer doses: validation with the 5-HT1A ligand [(18)F]FPWAY.
Ma Y; Lang L; Reyes L; Tokugawa J; Jagoda EM; Kiesewetter DO
Nucl Med Biol; 2009 May; 36(4):389-93. PubMed ID: 19423006
[TBL] [Abstract][Full Text] [Related]
10. Species differences in metabolites of PET ligands: serotonergic 5-HT1A receptor antagonists 3-trans-FCWAY and 3-cis-FCWAY.
Ma Y; Lang L; Kiesewetter D; Jagoda E; Eckelman WC
Nucl Med Biol; 2006 Nov; 33(8):1013-9. PubMed ID: 17127175
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and in vitro evaluation of bridgehead fluoromethyl analogs of N-{2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl}-N-(pyridin-2-yl)cyclohexanecarboxamide (WAY-100635) for the 5-HT(1A) receptor.
Al Hussainy R; Verbeek J; van der Born D; Booij J; Herscheid JK
Eur J Med Chem; 2011 Dec; 46(12):5728-35. PubMed ID: 22000209
[TBL] [Abstract][Full Text] [Related]
12. Fluoro analogs of WAY-100635 with varying pharmacokinetics properties.
Lang L; Jagoda E; Schmall B; Sassaman M; Ma Y; Eckelman WC
Nucl Med Biol; 2000 Jul; 27(5):457-62. PubMed ID: 10962250
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and in vivo biodistribution of F-18 labeled 3-cis-, 3-trans-, 4-cis-, and 4-trans-fluorocyclohexane derivatives of WAY 100635.
Lang L; Jagoda E; Ma Y; Sassaman MB; Eckelman WC
Bioorg Med Chem; 2006 Jun; 14(11):3737-48. PubMed ID: 16488611
[TBL] [Abstract][Full Text] [Related]
14. Development of 5-HT1A receptor radioligands to determine receptor density and changes in endogenous 5-HT.
Jagoda EM; Lang L; Tokugawa J; Simmons A; Ma Y; Contoreggi C; Kiesewetter D; Eckelman WC
Synapse; 2006 May; 59(6):330-41. PubMed ID: 16440292
[TBL] [Abstract][Full Text] [Related]
15. Development of fluorine-18-labeled 5-HT1A antagonists.
Lang L; Jagoda E; Schmall B; Vuong BK; Adams HR; Nelson DL; Carson RE; Eckelman WC
J Med Chem; 1999 May; 42(9):1576-86. PubMed ID: 10229627
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
